USPH
U S PHYSICAL THERAPY INCPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Feb 26 U.S. Physical Therapy reported strong 2025 financial results with 16…
- S Mar 6 to Mar 11 3 days of insider sells: $445.8K by 2 insiders, avg $81.50
- R Apr 15 U.S. Physical Therapy, Inc. (USPH) entered into a $450 million credi…
- R May 6 USPH reported Q1 2026 revenue of $198.3M (+7.9% YoY), but GAAP net i…
- B Jun 8 to Jun 12 3 days of insider buys: $48.8K by 1 insider, avg $62.54
- B Sep 11 1 insider buy $416.33 at $79.00
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $49.3K at an average $62.65. 2 insiders sold $445.8K. Price is 42% above their cost.
- InstitutionsBEARISH
Q2 2026: 12 added (0 new), 18 trimmed or exited.
- AnalystsBULLISH
11 of 13 rate it Buy or better. Every target is above the price.
- TrendUPTREND
8% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | TRIM | $48.0M |
| Neuberger Berman Group LLC | DOUBLED | $41.1M |
| AMERICAN CENTURY COMPANIES INC | ADD | $38.4M |
| SCHRODER INVESTMENT MANAGEMENT GROUP | ADD | $29.9M |
| BANK OF AMERICA CORP /DE/ | TRIM | $19.4M |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | $14.0M |
| SEI INVESTMENTS CO | TRIM | $5.9M |
| CITADEL ADVISORS LLC | DOUBLED | $5.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +9%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 11, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 10, 2026 | Barrington Research MAINTAIN | Outperform |
| Jun 24, 2026 | Citizens REITERATE | Market Outperform |
| May 13, 2026 | Barrington Research MAINTAIN | Outperform |
| May 8, 2026 | Citizens MAINTAIN | Market Outperform |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 1, 2026 | Davis Myra Director | AWARD | 1,210 sh |
| Sep 14, 2026 | Etta Nchacha EVP & Chief Financial Officer | AWARD | 6,831 sh |
| Sep 11, 2026 | Minan Peter Francis Director | BUY | $416.33 |
| Aug 20, 2026 | REEVE GRAHAM D. COO | TAX W/H | $59.4K |
| Aug 20, 2026 | Binstein Richard EVP Gen'l Counsel & Secretary | TAX W/H | $35.1K |
| Aug 20, 2026 | CURTIS JASON TRAVIS Interim CFO | TAX W/H | $3.1K |
| Aug 20, 2026 | Williams Eric Joseph President and COO | TAX W/H | $55.7K |
| Jun 12, 2026 | Minan Peter Francis Director | BUY | $57.85 |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
| Date | Member | Type | Amount |
|---|---|---|---|
| Jul 16, 2026 | Gilbert Cisneros D· HOUSE· US Physical Therapy Inc | BUY | $1,001 - $15,000 |
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 2 bullish · 1 bearish · 1 mixed · 1 neutral- NEUTRAL SC 13GOct 13, 2026
Copeland Capital Management, LLC filed a Schedule 13G disclosing a 6.3% passive stake in U.S…
Copeland Capital's 6.3% passive stake is a routine disclosure for a fund crossing the 5% threshold. No activist intent is signaled. Monitor future 13G amendments for any accumulation above this…
- MIXED 8-KAug 10, 2026
USPH reported Q2 2026 results with total revenue of $214M (+8.5% YoY) and PT revenue of $182M…
The core operating story is solid — record volumes and pricing — but near-term earnings are being compressed by transitory medical costs and hospital affiliation startup expenses. The H2 margin…
- BEARISH 8-KMay 6, 2026
USPH reported Q1 2026 revenue of $198.3M (+7.9% YoY), but GAAP net income fell to $5.0M from $9.9M…
The miss on the Street-tracked non-GAAP EPS metric may weigh on the stock in the near term, but reaffirmed guidance and revenue growth provide support. Focus on the conference call for hospital…
- BULLISH 8-KApr 15, 2026
U.S. Physical Therapy, Inc. (USPH) entered into a $450 million credit facility, consisting of a…
The new credit facility provides USPH with increased financial flexibility and a longer maturity profile, which supports its growth strategy and shareholder return initiatives. Traders should…
All USPH filing & press-release reports (5)
- SC 13G reportOct 13, 2026
- 8-K reportAug 10, 2026
- 8-K reportMay 6, 2026
- 8-K reportApr 15, 2026
- 8-K reportFeb 26, 2026